Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
about
Chronic myeloid leukemia: reminiscences and dreamsDrug Therapy in the Progressed CML Patient with multi-TKI FailureTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.How we will treat chronic myeloid leukemia in 2016.Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Update on emerging treatments for chronic myeloid leukemia.Chronic myeloid leukemia: Second-line drugs of choice.The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.Current trends in molecular diagnostics of chronic myeloid leukemia.Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity.Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia.Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibResponse to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemiaA case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report
P2860
Q26748769-B2D600F4-8BAC-4D4E-B398-301B7152FC59Q28085353-69408EB1-776B-43F8-94F6-079FA0B80984Q30242015-8D1E6D99-39A0-48AA-A94C-9AB47F247185Q30847302-0A102A5B-F6CA-4640-B332-D63E93F841D8Q33426475-13B4A63D-2564-48B2-AE80-91D50D277061Q33434675-F86F10C6-2052-4ED4-BF35-39690D6B50B0Q33442587-DFED02A8-A254-4ACE-85F3-7260EA86439DQ35269378-D56D4073-3982-44FB-A160-73D5ABD1DC21Q36533121-6CD92F66-8738-430A-9BE1-17CD8C324A60Q37361527-4F0B9FA0-39A2-4AC3-ADAA-14F35F79C005Q37461942-4FEC6A0D-5AE1-4E56-86A1-D2D85813E89FQ37579983-C4EBADF3-982A-4012-9504-3C0E63ED96B2Q38363058-027ED52D-5FF8-43FB-A38E-6BD45D65E7D6Q38392673-B7969E8D-4EB1-409F-938A-2C578D1B99BDQ38397515-7A1B3D92-19F1-4004-B5EE-A1F4E2CE139CQ38640422-89F910C8-0B73-4E52-AC3D-CF715821CC0BQ38642952-1FE99907-34F9-48AA-AF89-0D6B8F16982FQ38753313-D80817F2-396C-41C5-A692-119D4E545BBEQ38787015-EF42DC6C-3D29-499D-A82E-B900CCE7688AQ39186183-98DEA232-FF76-4A51-8C4B-26B3C3A5785EQ39310587-D14B6965-6279-4F69-8883-971C10D3D81BQ39339523-6EFD4E34-2628-4EA4-93E9-ED36AF616B14Q40053971-6DDE0DEC-726C-4FA3-A481-B4A776013340Q40178701-495CA80D-6C3E-4355-9C82-9C519B057893Q40519372-1A242F00-744C-4B98-9300-EEE6E45C9679Q40957470-E725E4FF-8C6A-43CA-9474-F9C54B295220Q41304682-8527A705-E5F0-4192-B56E-608602F39CFEQ43162253-9AA5BA18-A2BB-4D37-9097-4279FE8C154CQ47216949-8B4C2CF4-F5D6-46BB-8260-C13E71FA9D1DQ48124245-2CD8DA40-AE8F-4460-9221-338D6FFDD43CQ49553324-1BACFEC3-A2E1-479E-8A27-83A477F43BFAQ50068063-89CCE24C-6FE9-469B-BE35-D26791810546Q50997822-B5C8AF6D-7CF9-45E3-9311-7E1DBD80087FQ51415497-BA767A4C-C338-409F-A1BF-EA9B88404C95Q52571134-02D0C97A-CB93-4993-9AE3-DB91D3977B35Q52724715-48807021-B291-4BA5-BBA4-4B2D4EDE3CDCQ54962214-DCDBD854-4BDD-4505-92DA-27A3EF84227BQ56355417-9377631C-401D-4F2C-9C03-307BD69B2E43Q58754874-53941650-E560-4FD8-930E-4A5A3D46E8FE
P2860
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Bosutinib safety and managemen ...... her tyrosine kinase inhibitors
@ast
Bosutinib safety and managemen ...... her tyrosine kinase inhibitors
@en
type
label
Bosutinib safety and managemen ...... her tyrosine kinase inhibitors
@ast
Bosutinib safety and managemen ...... her tyrosine kinase inhibitors
@en
prefLabel
Bosutinib safety and managemen ...... her tyrosine kinase inhibitors
@ast
Bosutinib safety and managemen ...... her tyrosine kinase inhibitors
@en
P2093
P2860
P50
P1433
P1476
Bosutinib safety and managemen ...... her tyrosine kinase inhibitors
@en
P2093
Dong-Wook Kim
H Jean Khoury
Kathleen Turnbull
Nadine Besson
Simon Durrant
Tim H Brümmendorf
Virginia Kelly
P2860
P304
P356
10.1182/BLOOD-2013-07-513937
P407
P577
2013-12-17T00:00:00Z